Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9760026 | 1.00 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL9760034 | 1.00 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL7294575 | 0.88 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2CHRM2CHRM3 | |
| SCHEMBL7294562 | 0.88 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2CHRM2CHRM3 | |
| SCHEMBL7294568 | 0.88 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2CHRM2CHRM3 | |
| SCHEMBL13566528 | 0.87 | KMT2A (0.41) | MEN1KMT2ASMN1; SMN2L3MBTL1CHRM2 | |
| SCHEMBL14286832 | 0.86 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL15189740 | 0.84 | L3MBTL1 (0.38) | MEN1KMT2ASMN1; SMN2L3MBTL1CHRM2 | |
| SCHEMBL3872359 | 0.84 | KMT2A (0.46) | MEN1KMT2AL3MBTL1KDM4EBRD4 | |
| SCHEMBL14301507 | 0.79 | OPRM1 (0.40) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919909-B1 | SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARMETHEON INC (US) | 2013-08-21 | — | — | EP | claimed |
| US-7326787-B2 | Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2008-02-05 | — | — | US | claimed |
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-25 | — | — | US | disclosed |
| EP-4146625-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2023-03-15 | — | — | EP | disclosed |
| CN-115515933-A | Translumenally acting N- (piperidin-4-yl) benzamide derivatives | 武田药品工业株式会社 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021225968-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021225968-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-11 | — | — | WO | disclosed |
| US-8524736-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARMETHEON, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524736-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARMETHEON, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2007005951-A2 | STEREOISOMERIC PYRIDYL AND PYRIDONYL COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005951-A2 | STEREOISOMERIC PYRIDYL AND PYRIDONYL COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-1704146-A1 | STEREOISOMERIC COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | Aryx Therapeutics (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050197363-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2005-09-08 | — | — | US | disclosed |
| US-20050176757-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005068461-A1 | STEREOISOMERIC COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005068461-A1 | STEREOISOMERIC COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS (US) | 2005-07-28 | — | — | WO | disclosed |
| US-5041454-A | Stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-08-20 | — | — | US | disclosed |
| US-4975439-A | Gastrointestinal motility stimulating properties | JANSSEN PHARMACEUTICAL N.V. (BE) | 1990-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176757-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | CCKBR, GRPR, HRH2 | MEN1 783/4885KMT2A 3667/4885SMN1; SMN2 95/4885 |
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | HTR4, HTR1A, HTR1D | MEN1 1932/4885KMT2A 2584/4885SMN1; SMN2 655/4885 |
| US-20050197363-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | CCKBR, GRPR, HRH2 | MEN1 783/4885KMT2A 3667/4885SMN1; SMN2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.